Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04193566
Other study ID # H-19052662
Secondary ID 2019-004557-92
Status Completed
Phase Phase 4
First received
Last updated
Start date February 1, 2020
Est. completion date January 1, 2021

Study information

Verified date January 2021
Source Steno Diabetes Center Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes. The exact mechanisms of the beneficial effects of SGLT2 inhibition (SGLT2i) are still unknown. Kidney hypoxia has been demonstrated in diabetic kidney disease and SGLT2i is thought to relieve hypoxia in the kidneys. Mitochondrial dysfunction and autonomic dysfunction might also contribute to kidney hypoxia. Objective: The primary aim of the study is to assess the acute effects of SGLT2 inhibition on parameters reflecting oxygenation and oxygen consumption of the human kidney in persons with type 1 diabetes. Exploratory aims are to investigate acute changes in oxygen availability and oxygen access to the kidneys after SGLT2i. This include measures of peripheral blood oxygenation, mitochondrial function and autonomic function. Methods: Acute intervention study with oral dapagliflozin given in two doses each of 50 mg or matching placebo as intervention. Kidney oxygenation and perfusion parameters will be assessed by blood-oxygen-dependant level magnetic resonance imaging. Mitochondrial function will be assessed by extracellular flux analysis on lymphocytes. Autonomic function will be assessed by measuring baroreflex sensitivity. Design: Randomized, double blinded, placebo-controlled, cross-over intervention study. Study population: Fifteen healthy controls are recruited by advertisement and 15 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen. Endpoints: Primary end-point: Renal cortical and medullary oxygenation (T2*). Exploratory end-points: Renal cortical and medullary perfusion, renal artery flow, renal oxygen consumption, peripheral capillary oxygen saturation (SpO2), arterial oxygen partial pressure (PaO2), arterial oxygen saturation (SaO2), lymphocyte mitochondrial function, baroreflex sensitivity. Timeframe: Inclusion of patients from January 2020. Last patient last visit January 2021. Data analysis completed spring 2021, presentation autumn 2021 and publications Winter 2021.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 1, 2021
Est. primary completion date September 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria healthy controls: - Written informed consent must be provided before participation - Male or female patients > 18 years of age - Capable of lying in a MR-scanner for two hours Inclusion criteria persons with type 1 diabetes: - Written informed consent must be provided before participation - Male or female patients >18 years of age with a diagnosis of type 1 diabetes (WHO criteria) - Urinary albumin creatinine ratio (UACR) =30 mg/g in 2 out of 3 consecutive samples (albuminuria) prior to randomization assessed from electronic laboratory database. - Capable of lying in a MR-scanner for two hours Exclusion criteria for all: - Non-diabetic kidney disease as indicated by medical history and/or laboratory findings - Renal failure (eGFR<15 ml/min/1.73m2), dialysis or kidney transplantation - Treatment with beta-blocking medication - Uncontrolled arrhythmia, 2. or 3. degree AV-block or sick sinus syndrome - assessed from a standard 12-lead electrocardiogram - Pregnancy or breastfeeding (urine HCG is performed on all fertile women) - Systolic blood pressure < 90 or > 200 mmHg - Patients who, in the judgement of the investigator, is incapable of participating - Exclusion criteria for MRI - Claustrophobia - Known heart disease - Known lung disease - Have had surgery the past six weeks - Have foreign bodies of metal in the body (e.g. pacemaker, metal plates, metal screws) - Exclusion criteria for arterial blood gas sampling (only patients with type 1 diabetes) - Absent pulse - Raynauds syndrome - Buergers Disease (thromboangiitis obliterans) - Inadequate or interrupted circulation - Anticoagulation treatment - Coagulopathies (hypo or hyper coagulable states) - Arterial atherosclerosis - Insufficient collateral perfusion - Partial or full thickness burns over the cannulation site - Synthetic arterial or vascular grafts or infection at the proposed site of cannulation Patients with type 1 diabetes will have the possibility to participate in the study without getting arterial blood gas sampling.

Study Design


Intervention

Drug:
Forxiga
Forxiga®, dapagliflozin 10 mg film-coated tablet. For further information please refer to: https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf. Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.

Locations

Country Name City State
Denmark Steno Diabetes Center Copenhagen Gentofte

Sponsors (3)

Lead Sponsor Collaborator
Steno Diabetes Center Copenhagen Glostrup University Hospital, Copenhagen, Novo Nordisk A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Renal oxygenation Blood Oxygen Level Dependent (BOLD) Magnetic Resonance Imaging (MRI) assessing the transverse relaxation time of atomic nuclei in the tissue (T2*) in miliseconds (ms). From baseline to +3 hours from intervention
Primary Change in Renal oxygenation BOLD MRI assessing the transverse relaxation time of atomic nuclei in the tissue (T2*) in miliseconds (ms). From baseline to +6 hours from intervention
Secondary Change in renal cortical and medullary perfusion Renal tissue perfusion can be measured noninvasively with MRI using arterial spin labelling (ASL). It is measured in mL/g/min. From baseline to +3 hours from intervention
Secondary Change in renal cortical and medullary perfusion Renal tissue perfusion can be measured with MRI using arterial spin labelling (ASL). It is measured in mL/g/min. From baseline to +6 hours from intervention
Secondary Change in renal artery flow Renal artery flow can be measured by using phase contrast (PC) MRI. It is measured in mL/min. From baseline to +3 hours from intervention
Secondary Change in renal artery flow Renal artery flow can be measured by using phase contrast (PC) MRI. It is measured in mL/min. From baseline to +6 hours from intervention
Secondary Change in renal oxygen consumption Renal oxygen consumption can be measured using Q-flow combined with BOLD MRI. It is measured in pmol/min/microgram protein. From baseline to +3 hours from intervention
Secondary Change in renal oxygen consumption Renal oxygen consumption can be measured using Q-flow combined with BOLD MRI. pmol/min/microgram protein From baseline to +6 hours from intervention
Secondary Change in peripheral capillary oxygen saturation (SpO2) Pulse oximetry on index finger of the right hand. Estimates blood oxygen saturation from capillary blood. Measured in %. From baseline to +3 hours from intervention
Secondary Change in peripheral capillary oxygen saturation (SpO2) Pulse oximetry on index finger of the right hand. Estimates blood oxygen saturation from capillary blood. Measured in %. From baseline to +6 hours from intervention
Secondary Change in blood oxygen partial pressure (PaO2) Blood gas analysis on arterial blood. Measured in kPa. From baseline to +3 hours from intervention
Secondary Change in blood oxygen partial pressure (PaO2) Blood gas analysis on arterial blood. Measured in kPa. From baseline to +6 hours from intervention
Secondary Change in arterial blood oxygen saturation Blood gas analysis on arterial blood. Measured in %. From baseline to +3 hours from intervention
Secondary Change in arterial blood oxygen saturation Blood gas analysis on arterial blood. Measured in %. From baseline to +6 hours from intervention
Secondary Change in Peripheral Blood Monocyte mitochondrial function Seahorse X96 analyzer. Analyzes the oxygen consumption rate (OCR), measured in pMoles/min. From baseline to +12 hours from intervention
Secondary Change in levels of circulating inflammatory markers Commercially available panel from the company Olink. Includes 92 biomarkers. Information on the panel can be found here: https://www.olink.com/products/inflammation/#. From baseline to +12 hours from intervention
Secondary Change in baroreflex sensitivity Calculated from continous blood pressure and the distance between the R-waves in a continuous ecg. Baroreflex sensitivity describes how much heart-rate changes when blood pressure changes. Assessment of baroreflex sensitivity is done in a measurement of 5 minutes. The unit is ms/mmHg. From baseline to +12 hours from intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4